Association of Psychological Distress in Patients With Lung Cancer

the Association of Psychological Distress in Patients With Advanced Lung Cancer Treated With Immunotherapy or Targeted Therapy

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06218901

Acronym

Life-Score

Enrollment

500

Registered

2024-01-23

Start date

2016-01-01

Completion date

2028-12-31

Last updated

2025-05-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

IMMUNOTHERAPY, Lifestyle, Healthy, Lung Neoplasms, Prognosis Factors, Psychological Distress, Targeted Molecular Therapy

Brief summary

Psychological distress is a multi-factorial experience of a psychological, social, spiritual, and/or physical nature that may interfere with one's ability to cope effectively with cancer, physical symptoms and treatment. Psychological distress is common and affects the efficacy and prognosis of patients with lung cancer. The systematic anti-tumor therapy may effectively relieve psychological distress including anxiety, depression, and fatigue in patients with advanced lung cancer, the relief of the psychological distress can in turn improve the therapeutic effect. In summary, this study is to explore the associations of (dynamic) psychological stress with the efficacy and survival of anti-tumor therapy including immunotherapy and targeted therapy for advanced lung cancer patients.

Interventions

DRUGimmunotherapy

DRUGTargeted Therapy Agent

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

* Histologically proven diagnosis of lung cancer * 18 years of age or older * Ability to understand and the willingness to sign a written informed consent document

Exclusion criteria

* Not willing to participate in this clinical trial

Design outcomes

Primary

Measure	Time frame	Description
Objective response rate (ORR)	20 years	Collect detailed clinical information on patients with SCLC via the electronic medical records
Disease control rate (DCR)	20 years	Collect detailed clinical information on patients with SCLC via the electronic medical records
Progression-free survival (PFS)	20 years	Collect detailed clinical information on patients with SCLC via the electronic medical records

Secondary

Measure	Time frame	Description
Overall survival (OS)	20 years	Collect detailed clinical information on patients with SCLC via the electronic medical records

Countries

China

Contacts

Primary ContactXiaomin Niu

ar_tey@hotmail.com(86) 21 22200000

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026